TherapeuticsMD Files Q2 2024 10-Q
Ticker: TXMD · Form: 10-Q · Filed: Aug 12, 2024 · CIK: 25743
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceuticals
TL;DR
TherapeuticsMD filed its Q2 10-Q. Check financials.
AI Summary
TherapeuticsMD, Inc. filed its 10-Q for the quarterly period ended June 30, 2024. The company, formerly known as AMHN, Inc., is incorporated in Nevada and operates in the pharmaceutical preparations sector. Its principal executive offices are located at 951 Yamato Road, Suite 220, Boca Raton, FL 33431.
Why It Matters
This filing provides investors with the latest financial performance and operational updates for TherapeuticsMD, Inc. for the second quarter of 2024.
Risk Assessment
Risk Level: low — This is a routine quarterly filing providing standard financial and operational information.
Key Players & Entities
- TherapeuticsMD, Inc. (company) — Registrant
- June 30, 2024 (date) — Quarterly period end date
- AMHN, Inc. (company) — Former company name
- 951 Yamato Road, Suite 220, Boca Raton, FL 33431 (location) — Business and mailing address
FAQ
What is the filing date of this 10-Q report?
The filing date is August 12, 2024.
What period does this 10-Q cover?
This 10-Q covers the quarterly period ended June 30, 2024.
What is the company's Standard Industrial Classification (SIC) code?
The SIC code is 2834, for Pharmaceutical Preparations.
In which state was TherapeuticsMD, Inc. incorporated?
TherapeuticsMD, Inc. was incorporated in Nevada.
What is the company's SEC file number?
The SEC file number is 001-00100.
Filing Stats: 4,562 words · 18 min read · ~15 pages · Grade level 14.9 · Accepted 2024-08-12 17:16:27
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share TXMD The Nasdaq Stock Market
Filing Documents
- ea0210364-10q_therap.htm (10-Q) — 516KB
- ea021036401ex31-1_therap.htm (EX-31.1) — 9KB
- ea021036401ex31-2_therap.htm (EX-31.2) — 9KB
- ea021036401ex32-1_therap.htm (EX-32.1) — 4KB
- ea021036401ex32-2_therap.htm (EX-32.2) — 4KB
- 0001213900-24-067771.txt ( ) — 4043KB
- txmd-20240630.xsd (EX-101.SCH) — 48KB
- txmd-20240630_cal.xml (EX-101.CAL) — 40KB
- txmd-20240630_def.xml (EX-101.DEF) — 214KB
- txmd-20240630_lab.xml (EX-101.LAB) — 389KB
- txmd-20240630_pre.xml (EX-101.PRE) — 212KB
- ea0210364-10q_therap_htm.xml (XML) — 407KB
- Financial
Part I - Financial Information Item 1.
Financial statements
Financial statements (unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated 2 Condensed Consolidated 3 Condensed Consolidated 4 Notes to Unaudited Condensed Consolidated Financial Statements 5 Item 2. Management's discussion and analysis of financial condition and results of operations 16 Item 3. Quantitative and qualitative disclosures about market risk 26 Item 4.
Controls and procedures
Controls and procedures 26
- Other
Part II - Other Information Item 1.
Legal proceedings
Legal proceedings 28 Item 1A.
Risk factors
Risk factors 28 Item 2. Unregistered sales of equity securities and use of proceeds 28 Item 3. Defaults upon senior securities 28 Item 4. Mine safety disclosures 28 Item 5. Other information 28 Item 6. Exhibits 29
- Financial Information
Part I - Financial Information
Financial statements
Item 1. Financial statements TherapeuticsMD, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (in thousands, except per share data) June 30, 2024 December 31, 2023 (Unaudited) Assets: Current assets: Cash and cash equivalents $ 5,232 $ 4,327 Royalty receivable, current portion 2,908 3,090 Prepaid and other current assets 3,683 4,035 Current assets of discontinued operations — 344 Total current assets 11,823 11,796 License rights and other intangible assets, net 4,524 6,098 Right of use assets 6,497 6,873 Royalty receivable, long term 17,224 18,484 Other non-current assets 58 58 Total assets $ 40,126 $ 43,309 Liabilities and stockholders' equity: Current liabilities: Accounts payable $ 143 $ 27 Accrued expenses and other current liabilities 2,676 3,133 Current liabilities of discontinued operations 2,996 3,694 Total current liabilities 5,815 6,854 Operating lease liabilities 6,004 6,532 Other non-current liabilities 637 636 Total liabilities 12,456 14,022 Commitments and contingencies (Note 6) Stockholders' equity: Common stock, par value $ 0.001 ; 32,000 shares authorized, 11,532 issued and outstanding as of June 30, 2024 and December 31, 2023 11 11 Additional paid-in capital 979,124 978,917 Accumulated deficit ( 951,465 ) ( 949,641 ) Total stockholders' equity 27,670 29,287 Total liabilities and stockholders' equity $ 40,126 $ 43,309 The accompanying notes are an integral part of these condensed consolidated financial statements. 1 TherapeuticsMD, Inc. and Subsidiaries Condensed Consolidated Statements of Operations (Unaudited - in thousands, except per share data) Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Revenue, net: License and service revenue $ 234 $ 437 $ 547 $ 853 Operating expenses: Selling, general and administrative 1,233 2,781 2,555 5,837 Impairment of long-lived asse